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disease.6 Palmu and colleagues’ study complements 
their previous ﬁ ndings with this investigation of the 
eﬀ ect of PHiD-CV10 on secondary endpoints—non-
culture-conﬁ rmed, but suspected episodes of invasive 
pneumococcal disease. 
The ﬁ gure provides a schematic representation of the 
ﬁ ndings from the study by Palmu and colleagues and 
contrasts these with the previously reported eﬃ  cacy 
estimates of PHiD-CV10 in the prevention of culture-
conﬁ rmed invasive pneumococcal disease. For a ﬁ xed 
100 000 person-years of follow-up, the number of 
episodes of invasive pneumococcal disease expected 
in the absence of vaccination for each endpoint 
(irrespective of serotype) was estimated from incidence 
rates in children not randomly assigned to PHiD-CV10. 
Vaccination with PHiD-CV10 prevented invasive 
pneumo coccal disease episodes. The ﬁ gure also shows 
residual disease was present after vaccination, probably 
due to disease caused by non-vaccine serotypes, 
vaccine failure, or as a consequence of poor endpoint 
speciﬁ city. PHiD-CV10 vaccination resulted in high 
relative eﬃ  cacy when the primary endpoint of culture-
conﬁ rmed invasive pneumococcal disease was used, 
and roughly 61 such episodes were prevented.5 When 
the more sensitive but less speciﬁ c non-culture-
conﬁ rmed endpoints were assessed with veriﬁ ed 
suspected and all suspected invasive pneumococcal 
disease, the relative eﬃ  cacy estimates decreased but 
the estimated number of prevented episodes was 
2·3 and 3·4 times larger than were the reductions in 
culture-conﬁ rmed episodes, respectively. Thus, a large 
number of invasive disease episodes prevented were 
missed when investigators relied solely on culture-
conﬁ rmed detection. 
The ﬁ nding of increased absolute reductions in the 
burden of disease by use of sensitive rather than speciﬁ c 
endpoint deﬁ nitions is important for decision making 
about vaccination policies, and should serve as a lesson, 
both for trials and for continuing surveillance of vaccine 
eﬀ ectiveness. As Palmu and colleagues show, results 
based on cultures for detection of invasive pneumococcal 
disease can suggest a misleadingly low burden of disease, 
and the number of prevented cases estimated with this 
strategy might seem insuﬃ  cient to trigger action.1,7 With 
the powerful framework of a randomised study design, 
the investigators show that the beneﬁ ts of vaccination 
with pneumococcal conjugate vaccines extend far 
beyond traditional culture-conﬁ rmed detections. 
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Dose and timing of prenatal tobacco exposure: threats to 
early child development
For more than 50 years, we have known that prenatal 
tobacco exposure increases a child’s risk of low birth-
weight and prematurity.1 Recent studies have shown 
that in addition to negative growth and health 
consequences,2 prenatal nicotine exposure increases the 
risk of a wide range of behavioural and developmental 
problems, including attention deﬁ cit hyperactivity 
disorder,3 conduct disorders,4 externalising behaviour 
problems,5 and adolescent tobacco use.6 Although 
associations with cognition and language problems 
have been reported, they are less strong and enduring 
than the associations with behaviour problems.7  
Maternal tobacco use exposes the fetus to more than 
7000 chemicals, including nicotine. Nicotine acts as a 
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stimulant within the reward pathways and the nicotine 
receptors throughout the body, and is thought to cause 
hypoxia, to disrupt the nutrient supply, and to cause 
vasoconstriction of the placenta and umbilical vessels. 
The mechanisms linking nicotine to brain development 
are less clear, but might work through changes in 
metabolism and the neurotransmitter systems.8 These 
eﬀ ects could vary by dose and timing of the nicotine 
exposure; exposure during the embryonic stage is 
likely to cause diﬀ erent eﬀ ects from exposure later in 
pregnancy. The other chemicals in tobacco smoke might 
also play a part in disrupting early brain development; 
few have been studied individually.  
Sue Cooper and colleagues9 report the eﬀ ect of nicotine 
replacement therapy patches in 1050 pregnant smokers 
recruited at 12–24 weeks’ gestation. Their ﬁ nding that 
the intervention group experienced a reduction in 
smoking (validated by carbon monoxide concentration, 
salivary cotinine concentration, or both) 1 month after 
enrollment suggests that children in the intervention 
group had a varying period of lower tobacco exposure 
in the second-third trimester, despite no diﬀ erences in 
smoking at delivery. The subsequent ﬁ nding of higher 
rates of survival with no developmental impairment at 
2 years of age in the intervention group suggests that the 
nicotine patch was not harmful and could have reduced 
children’s prenatal tobacco exposure. However, questions 
arise regarding the mechanisms, including the timing and 
reduction in dose of tobacco are necessary to achieve a 
positive eﬀ ect. No diﬀ erences in birthweight, gestational 
age, or other birth outcomes were noted, suggesting 
that the mechanisms aﬀ ecting the tobacco–growth 
association diﬀ er from the mechanisms guiding the 
tobacco–brain development association. No information 
is provided about the children’s nutritional status 
at 2 years or about other environmental conditions 
that might aﬀ ect early development. The absence of 
diﬀ erences in rates of maternal smoking at the child’s 
age of 2 years and the low rates of smoking cessation 
(<3%) indicate that more eﬀ ective methods of smoking 
cessation during pregnancy are necessary. The ﬁ nding 
that nicotine causes cell damage and impairs synaptic 
activity has led to the recommendation of caution in the 
dose and timing of nicotine patches during pregnancy, 
especially if women continue to smoke.10  
A strength of the Cooper and colleagues’9 is the 
prospective assessment and the focus on child 
development at 2 years. Although early child develop-
ment is the genesis of adult health and wellbeing, 
many studies of smoking cessation during pregnancy 
terminate at delivery with the birthweight and 
gestational status of the newborn. By examination of 
children’s development beyond infancy, this Article 
generates a hypothesis by showing the need to address 
variability in the dose and timing of prenatal exposure 
to nicotine and other tobacco toxins. 
A 2014 report from the US Surgeon General11 
emphasises that prenatal nicotine exposure during 
fetal development adversely aﬀ ects maternal and 
fetal health during pregnancy, with lasting adverse 
consequences for brain development. In view of the 
negative consequences of prenatal nicotine and other 
tobacco toxin exposure worldwide, WHO recommends 
that pregnant women abstain from smoking.12 The 
eﬀ ectiveness of tobacco-control programmes varies 
widely across countries. Data from 15 European 
countries suggest that 26·2% of women smoke during 
pregnancy.13 In the USA, data from the National Survey 
on Drug Use and Health,14 indicate that in 2009–10, 
tobacco use in non-pregnant women was estimated 
at 26·7%, compared with 16·3% in pregnant women. 
In adolescents aged 15–17 years, the rate of smoking 
was higher in pregnant women (22·7%) than in non-
pregnant women (13·5%). Increases in electronic-
cigarette advertising and use in the youth throughout 
the world are further causes for concern.15
Three primary research agendas are urgently needed. 
The ﬁ rst is an understanding of the mechanisms whereby 
smoking during pregnancy disrupts prenatal brain 
development and functioning; convincing evidence 
shows that brain disruption occurs.4,8,11 Advanced neuro-
physiological and neurodevelopmental methods can 
provide additional evidence regarding the dose and 
timing of the nicotine exposure, along with exposure 
to the other chemicals, on fetal brain development. 
A second agenda involves investigation of the eﬀ ect 
of electronic cigarettes and other nicotine-containing 
vapour devices, and nicotine replacement patches used 
during pregnancy. The third agenda is the development 
and evaluation of eﬀ ective tobacco prevention and 
control strategies. Smoking rates in women are 
increasing globally, particularly in countries with low and 
middle incomes where there is often intensive marketing 
and little attention to the negative consequences of 
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smoking during pregnancy.16 Incorporating issues of 
empowerment and the social context of women into 
gender-based strategies for tobacco control could be an 
eﬀ ective strategy to reduce smoking during pregnancy13 
and to promote the health, development, and wellbeing 
of women and children.
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Bronchiectasis trials: losing the battle but winning the war?
The past several years have seen a growing interest 
in bronchiectasis from clinicians, academia, and 
industry. Having previously relied on extrapolating 
evidence from cystic ﬁ brosis, this renewed interest is 
now translating into a number of large randomised 
trials, speciﬁ cally in bronchiectasis. These eﬀ orts 
include recently published phase 3 trials of dry powder 
mannitol,1 colistin,2 and now in the Lancet Respiratory 
Medicine, inhaled aztreonam for patients with chronic 
Gram-negative airway infection.3 
This landmark study is the largest randomised trial in 
bronchiectasis so far conducted. 266 patients in AIR-
BX1 and 274 patients in AIR-BX2 were included in two 
identical double-blind placebo-controlled trials to assess 
the eﬃ  cacy and safety of two 28-day courses of inhaled 
aztreonam. The authors chose health-related quality of 
life as the primary outcome, using the newly developed 
Quality of Life-Bronchiectasis (QOL-B) questionnaire. 
The study seemed set to provide both a new treatment 
for bronchiectasis and a new validated clinical trial 
endpoint.  
Sadly, the trial’s primary endpoint was not met, 
and 22% of aztreonam-treated patients (29 of 134) 
discontinued treatment because of intolerance in 
AIR-BX1 (vs 3% [four of 132] in the placebo group), 
and 8% (11 of 135) discontinued aztreonam in AIR-
BX2 (vs 3% [four of 137] in the placebo group.3 Adverse 
eﬀ ects were mostly respiratory (dyspnoea and cough), 
mirroring eﬀ ects noted with previous inhaled agents 
such as tobramycin.4 Despite extensive subgroup 
analyses, a clear responder population could not be 
identiﬁ ed. 
Why did this therapy, which is eﬀ ective in cystic 
ﬁ brosis,5 not beneﬁ t patients with bronchiectasis? Some 
aspects of the study design might have contributed. The 
study included a broad, heterogeneous population of 
patients, including a mix of aetiologies, diﬀ erent Gram-
negative pathogens, and a range of severities. What 
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